Malignant Breast Neoplasm

1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistically significant difference in disease-free survi… (full text at CIViC)

PMID 24989892 · Norton et al., 2014 · Open in CIViC

81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, resp… (full text at CIViC)

PMID 23658459 · André et al., 2013 · Open in CIViC

In this phase II clinical trial, 40 patients with breast cancer harboring either FGFR1 or FGFR2 alterations (amplifications or mutations) were recruited. Of the 40 patients, 30 had FGFR1 alterations (… (full text at CIViC)

PMID 38354330 · Calfa et al., 2024 · Open in CIViC

PALOMA-3, a phase III, multicenter, double-blind randomized controlled trial enrolled patients with advanced estrogen receptor-positive breast cancer receiving fulvestrant (estrogen receptor antagonis… (full text at CIViC)

PMID 32940689 · O'Leary et al., 2021 · Open in CIViC

Amplification of FGFR1 is one molecular alteration associated with hormonal resistance and relapse in breast cancer. Using two different patient data cohorts (H12O - patients diagnosed at Hospital 12 … (full text at CIViC)

PMID 33579347 · Mouron et al., 2021 · Open in CIViC

In a cohort of 427 patients from the MONALEESA-2 study, which compared aramotase inhibitor letrozole plus CDK4/6 inhibitor ribociclib vs. letrozole plus placebo in patients with ER+/HER2− advanced bre… (full text at CIViC)

PMID 30914635 · Formisano et al., 2019 · Open in CIViC

FGFR1 expression, was assessed by IHC in 1,086 invasive breast cancers. FGFR1 expression was mainly associated with luminal cancer subtypes. Multivariate Cox regression analysis showed FGFR1 to be an … (full text at CIViC)

PMID 26673008 · Shi et al., 2016 · Open in CIViC

Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11… (full text at CIViC)

PMID 23658459 · André et al., 2013 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Patients with breast cancer had their tumor samples analyzed by Foundation Medicine in order to determine an appropriate clinical trial with targeted therapy or retrospectively to correlate with respo… (full text at CIViC)

PMID 27489863 · Wheler et al., 2016 · Open in CIViC

ERBB2-positive breast cancer cell lines including MDA-MB-361 and MDA-MB-453 were found to display outlier expression of FGFR4. Targeting FGFR4 in FGFR4 overexpressing ERBB2-positive breast cancer samp… (full text at CIViC)

PMID 24124571 · Li et al., 2013 · Open in CIViC

1,097 patients with breast cancer were evaluated for FOXP3 expression by IHC. FOXP3 expression was found in 405 tumor samples and associated with improved OS in patients treated with anthracycline-bas… (full text at CIViC)

PMID 22431701 · Ladoire et al., 2012 · Open in CIViC

This study showed that the carriers of the T allele had a significantly less favourable course of the disease when compared to carriers of the homozygous CC genotype. GNAS 393C homozygous patients of … (full text at CIViC)

PMID 17186357 · Otterbach et al., 2007 · Open in CIViC

To determine possible druggable gene targets, 18 histone deacetylases (HDACs) expression levels were evaluated from a cohort with 960 breast cancer samples and found that six of the HDACs (HDAC1, HDAC… (full text at CIViC)

PMID 28560068 · Shan et al., 2017 · Open in CIViC

As basal breast cancers display one of the most aggressive phenotypes in cell lines and commonly indicate poor prognosis in patients, assessing HDAC9’s variability among different cell types may evinc… (full text at CIViC)

PMID 26930713 · Lapierre et al., 2016 · Open in CIViC

A randomized phase III trial of hormone sensitive (ER or PR positive) early stage breast cancer (Dutch TEAM cohort, n=2,446) examined the addition of metformin to exemestane for 155 patients. IGF1R IH… (full text at CIViC)

PMID 26706833 · Engels et al., 2016 · Open in CIViC

In whole genome analysis of tumor and normal tissue from 97 breast cancers from TCGA, 132 kataegis loci were identified, and were enriched in chromosomes 8, 17, and 22, and depleted on chromosomes 2, … (full text at CIViC)

PMID 27373164 · D'Antonio et al., 2016 · Open in CIViC

gene expression assay performed earlier demonstrated a This case report of a patient with refractory breast angiosarcoma shows a potential therapeutic benefit of sunitinib due to the upregulation of V… (full text at CIViC)

PMID 25639617 · Silva et al., 2015 · Open in CIViC

123 patients with Cowden or Cowden-like syndrome (from the IRB8458-PTEN series) and 50 unaffected individuals without PTEN variants were analyzed for germline methylation and expression of PTEN and KI… (full text at CIViC)

PMID 21177507 · Bennett et al., 2010 · Open in CIViC

In the 746 metastatic breast tumors analyzed,KMT2C mutations were found in 9.8% of tumors, making it one of the most commonly mutated genes in breast cancer. Analysis of the 818 cases in the TCGA data… (full text at CIViC)

PMID 29755131 · Gala et al., 2018 · Open in CIViC

This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. … (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

In a clinical study of 49 patients, 10 patients with Breast Cancer (BC) and wild-type KRAS gene were treated with Cetuximab. After 16 weeks no clinical activity was observed. PFS of 6.7 weeks (95% CI,… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

A quantitative meta-analysis was performed to assess optimal IHC-calculated cutoff values for the prognostic use of proliferative biomarker Ki67 in breast cancer. The studies included ER positive and … (full text at CIViC)

PMID 26341751 · Petrelli et al., 2015 · Open in CIViC

MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Hig… (full text at CIViC)

PMID 26921265 · Tabouret et al., 2016 · Open in CIViC

MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low… (full text at CIViC)

PMID 26921265 · Tabouret et al., 2016 · Open in CIViC

MTAP and CDKN2A gene (RT-qPCR) and protein (western-blotting) expression as well as promoter methylation status were analyzed in breast cancer patients and seven breast cancer cell lines. Knockdown of… (full text at CIViC)

PMID 26751376 · de Oliveira et al., 2016 · Open in CIViC

MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1). Downstream signalling w… (full text at CIViC)

PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC

MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was ind… (full text at CIViC)

PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC

MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells)… (full text at CIViC)

PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC

MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling w… (full text at CIViC)

PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC

MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. These cells remained se… (full text at CIViC)

PMID 27279227 · Rodrik-Outmezguine et al., 2016 · Open in CIViC